Drug treatment of COVID-19 infection
G Lui, G Guaraldi - Current opinion in pulmonary medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States
AP Chokkalingam, J Hayden, JD Goldman… - JAMA Network …, 2022 - jamanetwork.com
Importance SARS-CoV-2, which causes COVID-19, poses considerable morbidity and
mortality risks. Studies using data collected during routine clinical practice can supplement …
mortality risks. Studies using data collected during routine clinical practice can supplement …
Expert consensus: main risk factors for poor prognosis in COVID-19 and the implications for targeted measures against SARS-CoV-2
FJ Candel, P Barreiro, M Salavert, A Cabello… - Viruses, 2023 - mdpi.com
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …
Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys
Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP …
Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and Omicron era: A real‐life cohort study
M Mazzitelli, M Trunfio, L Sasset… - Journal of Medical …, 2023 - Wiley Online Library
Recently, a benefit from administration of a 3‐day course of early remdesivir (ER) in the
outpatients' setting was reported. However, real‐life data on its use is scarce. Therefore, we …
outpatients' setting was reported. However, real‐life data on its use is scarce. Therefore, we …
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship
II Raad, R Hachem, N Masayuki, T Datoguia, H Dagher… - elife, 2023 - elifesciences.org
Background: In this international multicenter study, we aimed to determine the independent
risk factors associated with increased 30 day mortality and the impact of cancer and novel …
risk factors associated with increased 30 day mortality and the impact of cancer and novel …
Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
Background The respective benefits of high and low doses of dexamethasone (DXM) in
patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute …
patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute …
A peek into Pandora's box: COVID-19 and neurodegeneration
A Chandra, A Johri - Brain Sciences, 2022 - mdpi.com
Ever since it was first reported in Wuhan, China, the coronavirus-induced disease of 2019
(COVID-19) has become an enigma of sorts with ever expanding reports of direct and …
(COVID-19) has become an enigma of sorts with ever expanding reports of direct and …
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections
SJ Hurwitz, R De, JC LeCher, JA Downs-Bowen… - Viruses, 2024 - mdpi.com
Most repurposed drugs have proved ineffective for treating COVID-19. We evaluated median
effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical …
effective and toxic concentrations (EC50, CC50) of 49 drugs, mostly from previous clinical …
Coronaviral infection and interferon response: the virus-host arms race and COVID-19
The recent pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has resulted in unprecedented morbidity and mortality worldwide. The host cells use …
CoV-2) has resulted in unprecedented morbidity and mortality worldwide. The host cells use …